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Abstract
Several conserved neutralizing epitopes have been identified in the HIV Env protein and among these, the MPER of gp41
has received great attention and is widely recognized as a promising target. However, little success has been achieved in
eliciting MPER-specific HIV neutralizing antibodies by a number of different vaccine strategies. We investigated the ability of
HA/gp41 chimeric protein-based vaccines, which were designed to enhance the exposure of the MPER in its native
conformation, to induce MPER-specific HIV neutralizing antibodies. In characterization of the HA/gp41 chimeric protein, we
found that by mutating an unpaired Cys residue (Cys-14) in its HA1 subunit to a Ser residue, the modified chimeric protein
HA-C14S/gp41 showed increased reactivity to a conformation-sensitive monoclonal antibody against HA and formed more
stable trimers in VLPs. On the other hand, HA-C14S/gp41 and HA/gp41 chimeric proteins expressed on the cell surfaces
exhibited similar reactivity to monoclonal antibodies 2F5 and 4E10. Immunization of guinea pigs using the HA-C14S/gp41
DNA or VLP vaccines induced antibodies against the HIV gp41 as well as to a peptide corresponding to a segment of MPER
at higher levels than immunization by standard HIV VLPs. Further, sera from vaccinated guinea pigs were found to exhibit
HIV neutralizing activities. Moreover, sera from guinea pigs vaccinated by HA-C14S/gp41 DNA and VLP vaccines but not the
standard HIV VLPs, were found to neutralize HIV pseudovirions containing a SIV-4E10 chimeric Env protein. The virus
neutralization could be blocked by a MPER-specific peptide, thus demonstrating induction of MPER-specific HIV neutralizing
antibodies by this novel vaccine strategy. These results show that induction of MPER-specific HIV neutralizing antibodies can
be achieved through a rationally designed vaccine strategy.
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Introduction
It has been over 25 years since the identification of the human
immunodeficiency virus (HIV) as the causative agent of AIDS
[1,2]. However, the tremendous research effort has not yet yielded
an effective AIDS vaccine strategy. Earlier clinical trials using HIV
Env-based subunit vaccines elicited antibodies that reacted with
gp120 but were not neutralizing antibodies (NAbs), and vaccina-
tion failed to show protection against HIV infection [3–8]. The
failure of these trials promoted a shift to the development of HIV
vaccines that focus on eliciting T cell responses [9–11]. However,
the disappointing outcome from a recent clinical trial of a T-cell-
based vaccine regimen, the STEP trial conducted by Merck and
HIV Vaccine Trials Network (HVTN), dealt another setback to
AIDS vaccine development [12]. The failure of the STEP trial
further reinforced the notion that an effective AIDS vaccine will
need to induce both strong CTLs and broadly neutralizing
antibodies (bNAbs) against HIV infection [13–15]. Nevertheless,
effort to engineer vaccines that can induce HIV bNAbs has
encountered great difficulties. Extensive sequence variation of
concurrently circulating HIV strains poses a great challenge for
inducing HIV bNAbs [16]. While conserved neutralizing epitopes
have been identified in the HIV Env protein, induction of HIV
bNAbs against such epitopes has been difficult largely due to
camouflage of these cryptic sites by the highly variable sequences
in the HIV Env surface subunit gp120 [17]. This is supported by
structural studies of the HIV Env [18–20], which indicate that
conserved neutralizing epitopes are either hidden behind variable
loops or obscured by carbohydrates. Therefore, induction of HIV
bNAbs will require the design and development of novel vaccine
strategies that can overcome these obstacles.
The HIV Env transmembrane subunit gp41 serves to anchor the
Env protein to cellular and viral membranes and mediate
membrane fusion during virus entry into the cell. Although most
of gp41 appears to be occluded in the HIV Env, a number of studies
indicate that the membrane proximal external region of gp41
(MPER) is accessible to several HIV bNAbs and can be a promising
target for vaccine design [21]. Several monoclonal antibodies
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e14813(MAbs), which neutralize a broad range of primary HIV-1 isolates,
are known to bind to adjacent epitopes located in the MPER [22–
24]. The MPER is highly conserved and plays important roles in
HIV Env incorporation and virus entry into the cells [25,26], and
the identification of these conserved neutralizing epitopes in the
MPER spurred great effort to design vaccines for inducing HIV
bNAbs against this region [27]. However, little success has been
achieved by various approaches [28–33]. We previously reported
the construction of an HA/gp41 chimeric protein, in which the
gp120 subunit of HIV Env is replaced by the HA1 subunit of the
influenza virus A/Aichi/2/68 (H3N2) HA protein [34]. This
chimeric protein is efficiently transported to the cell surface and
exhibits enhanced reactivity to monoclonal antibodies 2F5 and
4E10. In this study, we evaluated the immunogenicity of HA/gp41-
based DNAandvirus-like particle(VLP) vaccinesinguinea pigs and
investigated their ability to present the conserved epitopes in MPER
for inducing MPER-specific HIV bNAbs.
Results
An unpaired Cys residue in HA/gp41 (Cys-14) affects
folding of the chimeric protein
The HA/gp41 chimeric protein was originally constructed by
fusing the HIV 89.6 Env gp41 to the C-terminus of the influenza
virus A/Aichi/2/68 (H3N2) HA1 subunit [34]. As a result, the
HA/gp41 chimeric protein contains an unpaired Cys residue, Cys-
14, at the N-terminal end of the HA1 subunit, which in the wild
type HA would form a disulfide bond with a Cys residue in the
HA2 subunit (Cys-137) as shown in Figure 1A. To investigate
whether this unpaired Cys-14 residue might affect the folding of
the HA/gp41 chimeric protein, it was changed into a Ser residue
by site-directed mutagenesis (amino acid sequence of this chimeric
protein is provided in Figure S1). The resulting chimeric protein,
designated as HA-C14S/gp41, was characterized for expression
and transport to the cell surface in comparison with HA/gp41. As
shown in Figure 1B, both the HA/gp41 and HA-C14S/gp41
chimeric proteins were expressed at comparable levels in the cells
and were efficiently transported to the cell surface similar to the
influenza HA, indicating that mutation of the Cys-14 residue did
not affect the expression and transport of the chimeric protein. We
next examined whether the mutation of the Cys-14 residue
affected the reactivity of the chimeric proteins expressed on the cell
surface to MAbs 2F5 and 4E10 by a cell surface ELISA. In
addition, to determine whether the mutation of the Cys-14 residue
may affect folding of the chimeric protein, we also included a MAb
(HC67) that is conformation-sensitive and only binds to influenza
HA under native and neutral pH conditions [35]. Further, a
polyclonal rabbit-anti-HA antibody (Jose4) was also included to
compare the level of protein expression on the cell surface. As
shown in Figure 1C, MAbs 2F5 and 4E10 as well as to the
polyclonal antibody Jose 4 bound to both HA/gp41 and HA-
C14S/gp41 chimeric proteins expressed on cell surfaces at similar
levels. However, whereas HC67 bound efficiently to the HA-
C14S/gp41 chimeric protein, this conformation-sensitive MAb
exhibited no significant reactivity with the HA/gp41 chimeric
protein. These results indicate that folding of the HA1 subunit of
the HA-C14/gp41 chimeric protein resembles more closely to the
wild type HA compared to the HA/gp41 chimeric protein. We
further carried out DNA immunization in mice to compare their
immunogenicities for inducing antibodies against gp41. As shown
in Figure 1D, although the differences are not statistically
significant (p.0.05), immunization with the HA-C14S/gp41
DNA induced higher levels of antibody responses against gp41
on average than those induced by the HA/gp41 DNA.
The HA-C14S/gp41 chimeric protein is incorporated into
VLPs and forms more stable trimers compared to the
HA/gp41 chimeric protein
After characterization of the HA/gp41 and HA-C14S/gp41
chimeric proteins, the genes for HA/gp41 and HA-C14S/gp41
were used to generate recombinant baculoviruses (rBV), designat-
ed as rBV-HA/gp41 and rBV-HA-C14S/gp41 respectively. These
rBVs were then used to produce VLPs by coinfection of SF9 insect
cells with rBV-SIV-Gag, a recombinant baculovirus that express
the SIVmac239 Gag protein. Incorporation of the HA/gp41 or
HA-C14S/gp41 chimeric proteins into VLPs were examined by
immuno-gold labeling coupled with electron microscopy. As
shown in Figure 2A, the HA/gp41 and HA-C14S/gp41 VLPs
exhibit similar morphology and size to the SIV Gag VLPs, and
both chimeric proteins were detected on the surface of VLPs by
immuno-gold labeling while no gold-particle labeling was seen on
SIV Gag VLPs. We further compared the oligomerization state of
HA-C14S/gp41 and HA/gp41 chimeric proteins in VLP
preparations by SDS-PAGE and Western blot analysis under
non-reducing conditions. As shown in Figure 2B, while trimers of
the chimeric proteins were detected in both HA-C14S/gp41 and
HA/gp41 VLPs, HA-C14S/gp41 maintained a significantly
higher portion of trimers than HA/gp41. Monomers were also
detected in both HA-C14S/gp41 and HA/gp41 VLPs as expected
since the protein oligomers are held by non-covalent bonds and
can dissociate from each other in SDS-PAGE gels. We further
compared the levels of HA/gp41 and HA-C14S/gp41 chimeric
proteins incorporated in VLPs by ELISA. As shown in Figure 2C,
similar amount of HA/gp41 or HA-C14S/gp41 chimeric proteins
was detected in VLP preparations with approximately 20 ng
chimeric protein in 1 mg VLPs, representing about 2% of the total
proteins in VLP preparations.
Immunization of guinea pigs with HA-C14S/gp41 DNA or
VLP vaccines induces antibodies against the HIV gp41
that exhibit HIV neutralizing activity
As shown in the above studies, the HA-C14S/gp41 chimeric
protein resembles more closely to the wild type HA in
conformation, exhibits improved immunogenicity in eliciting
antibodies against gp41, and forms more stable trimers in VLPs.
Based on these observations, the HA-C14S/gp41 DNA and VLP
vaccines were selected for immunization of guinea pigs to evaluate
their immunogenicities to induce HIV NAbs. As outlined in
Figure 3A, four groups of guinea pigs (4 in each group) were used
in this study and they were immunized 4 times by intramuscular
injections at 4-week intervals. Group 1 received 200 mg HA-
C14S/gp41 DNA vaccine and Group 2 received 100 mg HA-
C14S/gp41 VLPs. A third group (Group 3) received 100 mg SHIV
89.6 VLPs, which are comprised of SIV Gag and HIV 89.6 Env
(from which the gp41 portion of the HA-C14S/gp41 chimeric
protein is derived). A fourth group (Group 4) that serves
as a control group received 100 mg SIV Gag VLPs. Blood
samples were collected at 2 weeks after the second and fourth
immunizations for analysis of antibody responses. Only low levels
of antibodies against gp41 were induced after 2 immunizations in
Groups 1 and 2 that were immunized with HA-C14S/gp41 DNA
or VLP vaccines (data not shown). After 4 immunizations, both
HA-C14S/gp41 DNA and VLP vaccines induced significant levels
of antibody responses against gp41 (Figure 3B). Although
immunization with HA-C14S/gp41 VLPs induced higher levels
of gp41-specific antibodies on average than those induced by HA-
C14S/gp41 DNA vaccines, the differences are not statistically
significant between these two groups (p.0.05). In contrast, only
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PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e14813Figure 1. Characterization of the HA/gp41 and HA-C14S/gp41 chimeric proteins. A. Schematic diagram of the structure for influenza HA.
Shown in the diagram are the positions of the Cys 14 of HA1 and Cys137 of HA2, which form a disulfide bond in the HA protein, and the position of
the epitope (Ser 193 and Lys 156) recognized by the conformational antibody HC67 against HA. N1, C1, N2, and C2 represent N- and C-terminals of
the HA1 and HA2 subunits respectively. B. Intracellular and surface expression of the HA/gp41 and HA-C14S/gp41 chimeric proteins. Protein
expression was carried out using the recombinant vaccinia virus T7 expression system and detected by radioactive labeling coupled with surface
biotinylation and immunoprecipitation using antibodies against HA as described in Materials and Methods. Lanes M, molecular weight marker; lanes
1, mock transfection by a plasmid DNA vector; lanes 2, influenza HA; lanes 3, HA/gp41; lanes 4, HA-C14S/gp41. Arrow indicates the position of the HA,
HA/gp41, as well as HA-C14S/gp41 proteins in the SDS-PAGE. C. Comparison of antibody binding to HA, HA/gp41, and HA-C14S/gp41 by cell surface
ELISA. Protein expression was carried out in a 96-well plate in triplicates as described above. At 16 hr post transfection, cells were fixed and then
incubated with different antibodies at room temperature for 2 hr, including human MAbs 4E10 and 2F5 against gp41, rabbit polyclonal antibody
Jose4 against HA, and a conformation-sensitive mouse MAb HC67 against HA as indicated. After incubation with primary antibodies, HRP-conjugated
Goat-anti-human, rabbit, or mouse secondary antibodies were added to detect the amounts of the indicated antibody that bound to the cell surfaces,
which were expressed by the average O.D. value from the wells expressing each protein and binding to each primary antibody respectively. 1, mock
transfection by plasmid DNA vector; 2, influenza HA; 3, HA/gp41; 4, HA-C14S/gp41. D. Induction of gp41-specific antibodies by HA/gp41 and HA-
C14S/gp41 DNA vaccines in mice. Mice (groups of 6) were immunized by HA/gp41 and HA-C14S/gp41 DNA vaccines twice at 4-week intervals, and
blood samples were collected at 2 weeks after the second immunization for analysis of antibody responses against gp41 by ELISA. The levels of
antibodies against gp41 in sera from individual mice in each group were expressed by O.D. values at 1:500 serum dilution. Group1, immunization
with HA/gp41 DNA vaccine; Group 2, immunization with HA-C14S/gp41 DNA vaccine, Group 3, immunization with plasmid DNA vector pCAGGS.
doi:10.1371/journal.pone.0014813.g001
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zation with SHIV 89.6 VLPs, which were only slightly above the
background levels as detected in sera from control group guinea
pigs (Figure 3B). However, immunization with SHIV 89.6 VLPs
induced high levels of antibody responses against the HIV gp120,
whereas no significant level of gp120-specific antibodies was
induced by HA-C14S/gp41 DNA or VLP vaccines (Figure 3C). In
addition, immunization with both HA-C14S/gp41 DNA and VLP
vaccines also induced antibody responses against the HA protein
of the Aichi influenza virus, from which the HA1 subunit in the
HA-C14S/gp41 chimeric protein is derived (Figure 3D). Of
interest, while immunization with HA-C14S/gp41 DNA and VLP
vaccines induced similar levels of gp41-specific antibodies,
antibody responses against HA were significantly higher in guinea
pigs immunized with HA-C14S/gp41 VLPs than those induced by
the HA-C14S/gp41 DNA vaccine (p,0.05).
To determine whether HIV NAbs were induced, we analyzed
the activity of sera from immunized guinea pigs to neutralize
HIV pseudovirions. As expected, immunization by SHIV 89.6
VLPs induced NAbs against HIV 89.6 as well as SF162
pseudovirions while no significant neutralizing activity was
detected in sera from guinea pigs immunized with the control
SIV Gag VLPs (Figure 4A and 4B). Further, sera from all guinea
pigs immunized with HA-C14S/gp41 VLPs neutralized HIV
89.6 and SF162 pseudovirions at significant levels that are
comparable to those induced by SHIV 89.6 VLPs. In
comparison, sera from 2 out of 4 guinea pigs immunized with
the HA-C14S/gp41 DNA vaccine neutralized over 50% HIV
89.6 and SF612 pseudovirions at 1:50 dilution. In correlation
with antibody responses against gp41, sera with low levels of
gp41-specific antibodies neutralized HIV pseudovirions relative-
ly poorly compared to sera with higher levels of gp41-specific
antibodies. We further investigated whether immunization with
HA-C14S/gp41 DNA and VLP vaccines induced HIV bNAbs
by assessing their neutralizing activity against HIV pseudoviruses
prepared with primary HIV Env proteins. Three tier 2 HIV Env
including PVO.4 (SVPB11), AC10.029 (SVPB13), and
PRHPA4259 (SVPB 14) were selected from the standard HIV
subtype B panel compiled by Li et al. [36], which exhibit
moderate or low neutralization-sensitivity to HIV-1-positive
serum and high resistance to neutralization by V3-specific HIV
antibodies. As shown in Figure 4 (C–E), sera from guinea pigs
immunized with HA-C14S/gp41 DNA or VLP vaccines also
neutralized these pseudoviruses, although at reduced levels
compared to neutralization of HIV 89.6 and SF162 pseudovir-
ions. In contrast, sera from guinea pigs immunized with SHIV
89.6 VLPs did not exhibit significant neutralizing activities
against these pseudoviruses, similar to immunization with the
control SIV Gag VLPs. These results show that immunization
with HA-C14S/gp41 DNA and VLP vaccines induced NAbs
against both tier 1 and tier 2 HIV pseudoviruses, whereas
immunization with SHIV 89.6 VLPs only induced NAbs against
Figure 2. Characterization of the HA/gp41 and HA-C14S/gp41 VLPs. VLPs were produced in Sf9 insect cells using the recombinant
baculovirus expression system and purified through a sucrose gradient as described in Materials and Methods. A. Characterization of VLPs by
immune-gold-particle labeling and electron microscopy. Purified HA/gp41, HA-C14S/gp41, as well as the control SIV-Gag VLPs were coated onto a
sample grid and then incubated with rabbit-anti-HA antibody Jose4 followed by incubation with gold-particle-conjugated goat-anti-rabbit secondary
antibodies. The samples were then fixed with 1% uranyl acetate and then examined under an electron microscope. Arrows indicate gold-particle-
labeled glycoproteins on the surface of VLPs. B. Detection of HA/gp41 and HA-C14S/gp41 chimeric protein oligomers in VLPs by Western blot. VLPs
were lysed with 1% Triton X-100 and then mixed with non-reducing protein sample buffer followed by analysis by SDS-PAGE coupled with Western
blot using antibodies against HA (Jose4). Lane M, molecular weight marker; 1, HA-C14S/gp41 VLP, 2, control SIV Gag VLP; 3, HA/gp41 VLP.
C. Determining the amount of HA/gp41 and HA-C14S/gp41 chimeric proteins in VLPs by ELISA. VLPs were lysed with 1% Triton X-100 and then
coated onto a microtiter plate at 1 mg per well, and the amount of chimeric proteins were detected by ELISA using rabbit-anti-HA antibody Jose4.
Control wells were coated with 1 mg of SIV-Gag VLPs. A standard curve was constructed by coating the wells with serial dilutions of purified HA-histag
proteins in mixture with 1 mg SIV Gag VLPs and was used for calculating the amount of chimeric proteins in VLPs.
doi:10.1371/journal.pone.0014813.g002
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or the relatively easy-to-neutralize HIV SF162 Env proteins.
Immunization with HA-C14S/gp41 DNA and VLP vaccines
induced MPER-specific HIV NAbs
To determine whether antibodies against conserved neutralizing
epitopes in the MPER were induced, we compared the reactivity
of guinea immune sera against a synthetic peptide corresponding
to the epitopes recognized by MAbs 2F5 and 4E10. As shown in
Figure 5A, HA-C14S/gp41 DNA or VLP vaccines induced higher
levels of antibodies against the 2F5/4E10 peptide than the SHIV
89.6 VLPs. To investigate whether immunization with HA-C14S/
gp41 DNA or VLP vaccines induced MPER-specific HIV NAbs,
we constructed three chimeric proteins SIV-2F5, SIV-4E10, and
SIV-2F5/4E10 by engrafting the core epitope for MAb 4E10,
MAb 2F5, or both respectively into the SIVmac239 Env protein
similarly as described by Yuste et al. [37]. In addition, we also
introduced a truncation mutation in the cytoplasmic domain
(leaving 17 amino acids in the cytoplasmic tail) which has been
shown previously to increase surface expression and viral
incorporation of the SIVmac239 Env [38]. Characterization of
the SIV-4E10 chimeric protein showed that it was expressed on
the cell surfaces, exhibited cell fusion activities, and was able to
efficiently mediate pseudovirus infection. However, the SIV-2F5
and SIV-2F5/4E10 chimeric proteins exhibited low levels of cell
fusion activity and a poor ability to mediate pseudovirus infection,
similar as reported by Yuste et al. in their studies [37]. Further, the
SIV-4E10 pseudoviruses were neutralized by monoclonal antibody
4E10 as well as by sera from SIVmac239 infected monkeys, but
were resistant to neutralization by sera from HIV-infected patients
(data not shown). We thus employed the SIV-4E10-pseudoviruses
to test whether NAbs against the epitopes in the MPER of HIV
gp41 were induced in guinea pigs immunized with HA-C14S/
gp41 DNA or VLP vaccines. As shown in Figure 5B, sera from
guinea pigs immunized with HA/gp41 DNA or VLP vaccines
effectively neutralized SIV-4E10 pseudoviruses, at levels similar to
the neutralization of HIV SF162 or 89.6 pseudoviruses. In
contrast, sera from guinea pigs immunized with SHIV 89.6 VLPs
exhibited only low neutralizing activity against SIV-4E10
pseudoviruses that was only slightly above the background levels
as seen in sera from control guinea pigs. Further, none of the
serum samples neutralized infection by SIVmac239-pseudoviruses
Figure 3. Immunization of guinea pigs and analysis of antibody responses. Guinea pigs (groups of 4) were immunized 4 times at 4-week
intervals with HA-C14S/gp41 DNA (Group 1, 200 mg DNA per guinea pig per dose), HA-C14S/gp41 VLP (Group 2, 100 mg VLP per guinea pig per dose),
SHIV 89.6 VLP (Group 4, 100 mg VLP per guinea pig per dose), or SIV Gag VLP (Group 4, 100 mg VLP per guinea pig per dose) as indicated, and blood
samples were collected at 2 weeks after the second and fourth immunizations (A). The levels of antibody responses against HIV gp41 (B), HIV gp120
(C), or influenza HA (D) in sera from individual guinea pigs after 4 immunizations were determined by ELISA as described in Materials and Methods,
and were expressed by the O.D. values at indicated serum dilutions for each antigen.
doi:10.1371/journal.pone.0014813.g003
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DNA and VLP vaccines are specific for the conserved epitopes in
the MPER. To further confirm that neutralization of the SIV-
4E10 pseudovirions was mediated by antibodies against epitopes
in the MPER, we carried out a peptide competition assay. As
shown in Figure 5D, pre-incubation of sera from guinea pigs
vaccinated with HA-C14S/gp41 DNA or VLPs with the 2F5/
4E10 peptide but not a control peptide effectively blocked their
neutralizing activity against the SIV-4E10 pseudovirions. Taken
together, these results further demonstrate that immunization with
HA-C14S/gp41 DNA or VLPs induced MPER-specific HIV
NAbs in guinea pigs.
Discussion
Despite the sequence variation of the HIV Env protein, several
conserved neutralizing epitopes have been identified through
studies with human mAbs that exhibit broadly neutralizing
activities against HIV [13,15]. Among these conserved neutraliz-
ing epitopes, the MPER of gp41 has received great attention and
widely recognized as a promising target for inducing HIV bNAbs
[21,27]. However, development of a vaccine strategy to induce
HIV bNAbs against the conserved epitopes in MPER has been a
difficult task. In this study, we investigated the ability of a chimeric
protein HA/gp41, that exhibits enhanced reactivity to monoclonal
antibodies 2F5 and 4E10, to induce HIV bNAbs in guinea pigs.
Our results show that by mutating an unpaired Cys residue in its
HA1 subunit to a Ser residue, the modified chimeric protein HA-
C14S/gp41 exhibits increased reactivity to a conformation-
sensitive monoclonal antibody against HA and forms more stable
trimers in VLPs compared to the HA/gp41 chimeric protein.
Further, immunization of guinea pigs using the HA-C14S/gp41
DNA and VLP vaccines induced antibodies against the HIV gp41
that exhibit broadly HIV neutralizing activities. Moreover, by
using SIV-4E10 pseudovirions, we confirmed induction of HIV
NAbs against the conserved epitopes in the MPER of HIV gp41
by immunization with the HA-C14S/gp41 DNA and VLP
vaccines but not with SHIV 89.6 VLPs. Our results demonstrate
for the first time the induction of MPER-specific HIV NAbs by a
rationally designed vaccine strategy.
While the broadly neutralizing MAbs 2F5 and 4E10 against the
MPER were obtained from an HIV-infected patient, the presence
of such HIV NAbs is rare and can only be detected at low levels in
a small portion of HIV-infected patients [37,39–42]. One widely
recognized difficulty for inducing such HIV NAbs is that the
MPER is poorly accessible in native HIV Env due to shielding by
the gp120 subunit [16,21,27,43]. To overcome this difficulty, a
number of strategies have been investigated to induce HIV NAbs
against the conserved epitopes in the MPER including but not
limited to: engrafting the 2F5 epitope core sequence ELDKWAS
in the antigenic B site of an influenza virus HA [44]; construction
of a fusion protein between the gp41 MPER segment and the
porcine endogenous retrovirus Env p15E subunit [45]; grafting the
gp41 MPER segment into the V1/V2 region of HIV-1 Env gp120
[46]; presenting gp41 derivatives in pre-fusion state on HIV VLPs
[47]; presenting the MPER of gp41 on hepatitis B virus (HBV)
surface antigen particles [32]; construction of epitope-scaffolds to
present 2F5 and 4E10 epitopes [48,49]; as well as by production of
a trimeric MPER containing HA-gp41 fusion protein [33]. While
these different vaccine strategies induced antibodies against the
HIV gp41 and/or peptides corresponding to the epitopes in the
MPER, little success was achieved in eliciting HIV NAbs. Thus,
simply presenting the MPER segment in a more accessible form
alone may not be sufficient to induce HIV NAbs. Structural
analysis of the MAb 2F5 in complex with a peptide corresponding
to its epitope showed that 2F5 only binds to one face of the peptide
[50]. Further, the MPER has also been reported to form a kinked-
helix conformation on the membrane surface that is partially
buried into the membrane lipids [51]. Taken together, these
results indicate that it may be necessary to present the MPER in a
proper conformation to induce HIV NAbs in addition to
enhancing the exposure of these epitopes.
The results presented in this study show that the induction of
MPER-specific HIV NAbs can be achieved by a vaccine strategy
that meets the requirements mentioned above. In the design of the
HA/gp41 chimeric protein, the replacement of HIV gp120 with a
relatively smaller HA1 subunit from influenza virus HA resulted in
enhanced exposure of the MPER in gp41 and increased binding
activity to monoclonal antibodies 2F5 and 4E10 [34]. In the
present study, the HA/gp41 was further modified by mutation of
an unpaired Cys residue in the HA1 subunit and the resulting HA-
C14S/gp41 chimeric protein exhibits similar reactivity to MAbs
2F5 and 4E10 compared to HA/gp41, indicating that the
exposure of the MPER in the chimeric protein is not affected by
the mutation. Moreover, the HA-C14S/gp41 chimeric protein
retained reactivity to a conformation sensitive MAb HC67 against
the HA1 subunit, indicating that the folding of HA-C14S/gp41
resembles the wild type HA more closely in conformation. Further,
the HA-C14S/gp41 chimeric protein is also found to form more
stable trimers in VLP preparations. In addition, in both the DNA
and VLP vaccine platforms used in this study, the HA-C14S/gp41
chimeric protein is presented to the immune system in its
membrane anchored form. Thus, the key difference of this
vaccine strategy as compared to the others is that the MPER in the
HA-C14S/gp41 chimeric protein is presented in conformation
that more closely mimics its natural state, which may play a critical
role in the successful induction of MPER-specific HIV NAbs. By
immunization studies in guinea pigs, it was observed that the HA-
C14S/gp41 DNA and VLPs vaccines induced higher levels of
antibodies against the HIV gp41 as well as a peptide correspond-
ing to the MPER than SHIV 89.6 VLPs. Further, sera from HA-
C14S/gp41 DNA- or VLP-vaccinated guinea pigs exhibited
neutralizing activity against not only the HIV 89.6 and SF162
pseudoviruses but also four tier 2 primary HIV pseudoviruses as
well as the chimeric SIV-4E10 pseudoviruses. In contrast, sera
from SHIV VLP-vaccinated guinea pigs only neutralized HIV
89.6 and SF162 pseudoviruses but not the tier 2 primary HIV
pseudoviruses or the SIV-4E10 pseudovruses. These results
demonstrate that the HA-C14S/gp41 DNA and VLPs are more
Figure 4. Neutralization of HIV pseudovirions. Guinea pigs were immunized as described in Figure 3A and sera collected at 2 weeks after the
fourth immunization were analyzed for HIV neutralizing activity using a pseudovirion neutralization assay as described in Materials and Methods. HIV
pseudovirions were incubated with individual serum samples from vaccinated guinea pigs at 1:50 dilutions in 10% FCS-DMEM for 1 hr at 37uC and
then added to TMZ-bl cells seeded in a 96-well plate. Two days after infection, the medium was removed and the cells were fixed and stained for
b-galactosidase expressing cells. Neutralizing activity was expressed as the percentage of reduction in the number of b-galactosidase expressing cells
in sample wells compared to those in control wells (% neutralization). Group 1, HA-C14S/gp41 DNA; Group 2, HA-C14S/gp41 VLP; Group 3, SHIV 89.6
VLP; Group 4, SIV Gag VLP. A. Neutralization of HIV 89.6 pseudovirions; B, Neutralization of HIV SF162 pseudovirions; C, Neutralization of HIV PVO.4
(SVPB11) pseudovirions; D, Neutralization of HIV AC10.029 (SVPB13) pseudovirions; E, Neutralization of HIV PRHPA4259.7 (SVPB14) pseudovirions.
doi:10.1371/journal.pone.0014813.g004
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89.6 VLPs that contain a wild type HIV Env protein.
While the induction of MPER-specific HIV bNAbs represents a
significant advancement towards our goal, it is also noted that the
levels of such antibodies are still low. The low level of neutralizing
activity probably resulted from the relatively low level of MPER-
specific antibody responses induce by the HA-C14S/gp41 DNA
and VLP vaccines. This is similar to observations made using the
HBV surface antigen as a carrier, which also presents the MPER
in its membrane proximal form [32]. On the other hand,
immunization with a purified HA-gp41 chimeric protein that
consists the Heptad Repeat 1 (HR1) region of influenza HA plus
the Heptad Repeat 2 (HR2) and MPER regions of gp41 induced
high levels of antibodies against the HIV gp41, but no HIV NAbs
were detected [33]. Taken together, these results indicate that the
immunogenicity of the epitopes in the MPER may be weak when
the MPER is presented in its membrane associated conformation.
In addition, our results show that while immunization with HA-
C14S/gp41 DNA and VLP vaccines induced similar levels of gp41
as well as MPER-specific antibodies, immunization with VLPs
induced significantly higher levels of antibody responses against
the HA1 subunit of the chimeric protein. This observation
indicates that inducing an antibody response to weakly immuno-
genic epitopes may not be effectively augmented simply by using a
more immunogenic vaccine platform. Further, while immuniza-
tion with SHIV 89.6 VLPs also induced low levels of antibodies
against gp41 as well as the 2F5/4E10 peptide, no significant
neutralization of the SIV-4E10 pseudovirions was observed. Thus,
it is also possible that not all MPER-specific antibodies induced by
vaccinations are capable of neutralizing HIV infection. Additional
studies are necessary to determine the properties of the MPER-
specific HIV NAbs and to develop strategies to boost induction of
such antibodies.
In summary, the results in this study show that HIV NAbs can
be successfully induced against the conserved epitopes in the HIV
Env MPER. However, the neutralizing activity induced by HA-
C14S/gp41 DNA and VLP vaccines against HIV pseudovirions,
especially those containing Env from primary HIV isolates, is still
relatively weak. Further, the level of MPER-binding antibodies
induced by HA/gp41 based vaccines seems also to be lower
compared to other studies that reported induction of high levels of
MPER-binding antibodies with little to no HIV neutralizing
activity[33,46,47]. One possible explanation for these seemingly
paradoxical observations is that induction of such antibodies may
require presentation of MPER in a proper membrane associated
conformation and the MPER presented in such a form only
exhibits weak immunogenicity. Thus, new strategies are still
needed to be investigated to overcome this difficult and yet
important issue. Nonetheless, the success of this study paves the
way for future studies to development a more effective vaccine
strategy to induce HIV bNAbs against the conserved epitopes in
the MPER of the HIV Env.
Materials and Methods
Ethics statement
Animal ethics approval for the immunization studies in mice
and guinea pigs was obtained from the Institutional Animal Care
and Use Committee (IACUC) at the Emory University. All animal
studies were performed in compliance with the guidelines of the
Institutional Animal Care and Use Committee (IACUC) under
approval from the IACUC at the Emory University.
Cells, reagents, and animals
Hela cells and 293T cells were obtained from American Type
Culture Collection (ATCC) and TMZ-bl cells were obtained from
NIH AIDS Research and Reference Reagent Program (NIH
ARRRP). The cells were maintained in DMEM supplemented
with 10% fetal calf serum (FCS-DMEM). Human MAbs 2F5 and
4E10 and polyclonal antibodies against HIV (HIVIG) were
obtained from NIH ARRRP. Rabbit polyclonal antibodies against
the HA of influenza virus Aichi (Jose 4) and mouse MAb HC-67
that recognizes a conformational sensitive epitope in HA [35] were
kindly provided by Dr. David Steinhauer. Female Balb/c mice (8-
week old) and female guinea pigs (2 month old, weight 250 g) were
purchased from the Jackson Laboratory and housed in the animal
facility at the Emory University.
Gene construction and analysis of protein expression
Construction of the HA/gp41 gene has been described
previously ([34]). For construction of the HA-C14S/gp41 gene,
the codon for the Cys 14 residue in the HA/gp41 gene was
changed into the codon for a Ser residue by site-directed
mutagenesis (amino acid sequence of the HA-C14S chimeric
protein were provided in Figure S1). Protein expression was
analyzed using the recombinant vaccinia virus T7 (VTF7-3)
transient expression system. Briefly, 1066 HeLa cells were seeded
in 6-well plate and grown to 90% confluency overnight. The cells
were then infected with VTF7-3 which expresses the T7
polymerase for 2 hr followed by transfection with indicated
DNA constructs using Lipofectin (Invitrogen). At 12 hr post
transfection, cells were starved in Met, Cys-deficient DMEM for
30 min and then labeled with 100 uCi
35S-Met,Cys labeling mix
(Amersham) in 1 ml Met, Cys-deficient DMEM for 4 hr.
Following radioactive labeling, protein surface expression was
detected by a surface biotinylation assay as described in our
previous studies [52,53]. Briefly, after labeling, cells were washed
with phosphate-buffered saline (PBS) at 4uC and then incubated
with 2 ml of NHS-SS-biotin dissolved in PBS (0.5 mg/ml) for
Figure 5. Induction of MPER-specific HIV NAbs by immunization with HA-C14S/gp41 DNA and VLP vaccines. Guinea pigs were
immunized as described in Figure 3A and sera collected at 2 weeks after the fourth immunization were analyzed for the levels of MPER-specific
antibody responses by ELISA as well as their neutralizing activity against a conserved epitope in MPER that was recognized by the monoclonal
antibody 4E10 by a pseudovirion neutralization assay. A. Antibody responses against the MPER were determined by ELISA using the 2F5/4E10
peptide (ELLELDKWASLWNWFNITNW, a synthetic peptide corresponding to a segment in the MPER) as coating antigens, and expressed as the O.D.
values for each serum sample at 1:200 dilutions. SIV-4E10 (B) or SIVmac239 (C) pseudovirions were incubated with individual serum samples from
vaccinated guinea pigs at 1:50 dilutions in 10% FCS-DMEM for 1 hr at 37uC and then added to TZM-bl cells seeded in a 96-well plate. Two days after
infection, the medium was removed and the cells were fixed and stained for b-galactosidase expressing cells. Neutralizing activity was expressed as
the percentage of reduction in the number of b-galactosidase expressing cells in sample wells compared to those in control wells (% neutralization).
D. Peptide competition of SIV-4E10 pseudovirus neutralization by sera from guinea pigs vaccinated by HA-C14S/gp41 DNA and VLP vaccines. Guinea
pig sera (Group 1 and Group 2) were diluted in 10% FCS-DMEM at 1:40 and pre-incubated with 0.1 ug of the 2F5/4E10 peptide
(ELLELDKWASLWNWFNITNW) or a control peptide (AMQMLKETI, corresponding to a segment in the HIV Gag protein) at 37uC for 1 hr as indicated,
and then used in neutralization assay (at a final dilution of 1:50) against the SIV-4E10 pseudovirus. Group 1, HA-C14S/gp41 DNA; Group 2, HA-C14S/
gp41 VLP.
doi:10.1371/journal.pone.0014813.g005
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(150 mM NaCl/50 mM Tris HCl, pH 7.5/1 mM ethylenedi-
amine tetraacetate/1% Triton X-100/1% sodium deoxycholate),
and then immunoprecipitated with Jose4 antibodies and Protein
A-agarose bead at 4uC overnight. After immunoprecipitation,
samples were washed twice in lysis buffer plus 0.4% SDS and then
split into two equal portions. One portion (representing total
cellular expression of the chimeric proteins) was mixed with 15 ul
sample buffer (125 mM Tris-HCl [pH 7.5], 4% SDS, 20%
glycerol, plus 10% ß-mercaptoethanol) and heated at 95uC for
5 min before being analyzed by SDS-PAGE. The other portion
was mixed with 20 ul 10% SDS and heated at 95uC for 15 min to
dissociate protein-antibody-Protein A-agarose bead complex.
Dissociated proteins were then dissolved in 700 ul lysis buffer
and incubated with 10 ul Streptavidin-agarose bead for 5 h at 4uC
to precipitate biotinylated surface proteins. Biotinylated samples
(representing surface expression of the chimeric proteins) were
washed three times with lysis buffer, mixed with 15 ul sample
buffer, and heated at 95uC for 5 min before analysis by SDS-
PAGE.
Inparing reactivity of the chimeric proteins expressed on the cell
surface with different antibodies, we employed a cell surface ELISA
following established protocols [34]. Briefly, protein expression was
carried out in HeLa cells using the VTF7-3 transient expression
system. At 16 hr post transfection, the cells were fixed with 0.5%
glutaradehyde in PBS and then blocked with PBS containing 5%
(w/v) BSA. After washing with PBS, the cells were incubated with
the indicated primary antibodies (2F5, 4E10, HC67, or Jose 4
diluted in PBS at 1:1000) for 2 hr at room temperature, washed
again with PBS, and then incubated with corresponding HRP-
conjugated secondary antibodies diluted at 1:4000 in PBS (Goat-
anti-human for 2F5 and 4E10, Goat-anti-mouse for HC67, and
Goat-anti-rabbit for Jose4 antibodies respectively, R&D Systems)
for 1 hr at room temperature. The cell were washed again with PBS
to remove unbound antibodies and then substrate TMB (3,39,5,59-
tetramethylbenzidine, Sigma) was added for development of color.
The O.D. values, which represent the relative amount of bound
antibody, were read with an ELISA plate reader at the wavelength
of 450 nm.
VLP production and characterization
VLPs were produced in Sf9 insect cells (Invitrogen) using the
recombinant baculovirus (rBVs) expression system. Construction
of rBVs expressing the SIV Gag and HIV 89.6 Env proteins and
production of SHIV 89.6 VLPs have been described previously
[54,55]. The genes for the HA/gp41 and HA-C14S/gp41chiemric
proteins were cloned into the plasmid vector pFastBac (Invitrogen)
under the Pphol promoter and rBVs were generated using the
Bac-to-Bac Bacmid system (Invitrogen) following the manufactur-
er’s protocol, which were designated as rBV-HA/gp41 and rBV-
HA-C14S/gp41 respectively. For VLP production, Sf9 cells
(2610
6/ml) were co-infected by rBV-SIV Gag along with rBV-
HA/gp41 or rBV-HA-C14S/gp41 at MOIs (multiplicity of
infection) of 2 and 5 respectively, and VLPs released into the
medium were collected at 60 hr post infection. After clarification
of cell debris, VLPs were concentrated by ultra-centrifugation at
28,000 rpm for 40 min in an SW-28 rotor (Beckman)and further
purified through a discontinuous sucrose gradient (10–50%) by
ultra-centrifugation at 32,000 rpm for 1 hr in an SW-41 rotor
(Beckman). Purified VLPs were then concentrated by ultra-
centrifugation at 28,000 rpm for 40 min in an SW-28 rotor
(Beckman) and re-suspended in PBS. Protein concentration of
VLPs was determined using a BCA assay kit and the VLP
preparations were adjusted with PBS to a final protein
concentration of 1 mg/ml. SIV Gag VLPs, which were used as
control VLPs throughout this study, were produced by infecting
Sf9 cells with rBV-SIV-Gag alone and similarly purified through a
sucrose gradient.
Purified VLPs were characterized by Western blot for the
presence of HA/gp41 or HA-C14S/gp41 chiemric proteins.
For detecting oligomeric forms of HA/gp41 or HA-C14S/gp41
chiemric proteins in VLPs, samples were prepared by addition of
non-reducing sample buffer and heated at 72
oC for 5 min prior to
analysis by SDS-PAGE followed by Western blot using rabbit-anti-
HA antibodies (Jose4, diluted at 1:4000 in PBS) as the primary
antibody and HRP-conjugated, goat-anti-rabbit-IgG antibodies as
the secondary antibody (diluted at 1:5000 in PBS). Incorporation
of the HA/gp41 or HA-C14S/gp41 chimeric proteins in VLPs
was further examined by immunogold-particle labeling and
electron microscopy (EM). Briefly, purified VLPs were coated
onto a sample grid and incubated with rabbit-anti-HA antibodies
for 1 hr at room temperature. After removing unbound antibodies
by rinsing in PBS, the samples were incubated with gold-particle-
conjugated goat-anti-rabbit secondary antibodies for 1 hr at room
temperature, washed again by rinsing in PBS, followed by negative
staining with 1% (w/v) uranyl acetate and then examined with a
Hitachi-H7500 transmission electron microscope. The amounts of
HA/gp41 and HA-C14S/gp41 chimeric proteins in VLP
preparations were further determined by ELISA. VLPs were
lysed with 1% Triton X-100 and then coated onto a microtiter
plate at 1 mg per well in triplicates. Chimeric proteins were
detected by incubation with rabbit-anti-HA antibody (Jose 4) as
the primary antibody and then HRP-conjugated, goat-anti-rabbit-
IgG antibodies as the secondary antibody. Control wells were
coated with 1 mg of SIV-Gag VLPs. After a final wash, ABTS
(2,29-azino-bis(3-ethybenz-thiazoline-6-sulfonic acid), Sigma) dis-
solved in citrate phosphate buffer (3 mg ABTS in 10 ml CPB,
pH 4.2, plus 10 mlH 2O2) was added at 100 ml/well to develop
color and read by an ELISA plate reader at 405 nm. Absorption
values (O.D values) were recorded and presented as the levels of
chuimeric proteins in VLPs for comparison. A standard curve was
constructed by coating the microtiter plate with serial dilutions of
purified HA-histag protein mixed with 1 mg SIV Gag VLPs for
calculating the amount of chimeric proteins in VLPs.
Immunizations
The genes for the HA/gp41 and HA-C14S/gp41 chimeric
proteins were cloned into the plasmid vector pCAGGS as
described previously [34,52,53]. Plasmids were amplified in E.
coli DH5a, purified with a Qiagen Endo-Free Megaprep kit and
dissolved in sterile PBS at 1 mg/ ml. Mice (groups of 6) were
immunized twice at 4-week intervals with 100 mg of the indicated
DNA construct by intra-muscular injection in both quadriceps,
and blood samples were collected by retro-orbital bleeding at two
weeks after the second immunization. Sera were heat-inactivated
at 56uC for 30 min, and then stored at 280uC until analysis.
Guinea pigs (groups of 4) were immunized four times at 4-week
intervals with indicated the DNA vaccines (200 mg per guinea
pig per immunization) or VLPs (100 mg per guinea pig per
immunization) by intra-muscular injection in both quadriceps, and
blood samples were collected at two weeks after the second and
fourth immunizations through the cranial vena cava. Sera were
heat-inactivated at 56uC for 30 min, and then stored at 280uC
until analysis.
Analysis of serum antibody response by ELISA
Serum samples were analyzed by ELISA for antibody responses
against HIV gp41, HIV gp120, influenza virus Aichi HA, and a
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Purified gp120-histag, HA-histag, and HN/gp41-histag proteins
were produced as described previously [34,52,56]. Briefly, a
recombinant vaccinia virus expressing a gp12-histag, HA-histag,
or HN/gp41-histag protein (the gp120, HA1 subunit of Aichi
influenza virus HA, or the HN-gp41 fusion protein ectodomain
was fused with a histag segment HHHHHH at its C-terminus
respectively) was generated and used to infect Hela cells. At 48 hr
post-infection, histag proteins expressed in cells were purified using
Ni-NTA agarose beads (QIAGEN, Valencia, CA) and then
characterized by Coomassie Blue staining and Western blot. A
peptide (ELLELDKWASLWNWFNITNW) corresponding to a
segment of the gp41 MPER was synthesized at the Emory
University Microchamical Facility, which contains the core
epitopes for monoclonal antibodies 2F5 and 4E10 and was
designated as the 2F5/4E10 peptide (.70% pure).
For analysis of antibody responses against these different
antigens, microtiter plates were coated with different purified
proteins or the 2F5/4E10 peptide at 200 ng/well overnight, and
then incubated with collected serum samples diluted in PBS at
different dilutions as indicated for 2 hr at room temperature. After
wash, HRP-conjugated secondary antibodies (Sigma) against
mouse or guinea pig IgG were added to the plate and incubated
for 2 hr at room temperature. After a final wash, ABTS (2,29-
azino-bis(3-ethybenz-thiazoline-6-sulfonic acid), Sigma) dissolved
in citrate phosphate buffer (3 mg ABTS in 10 ml CPB, pH 4.2,
plus 10 mlH 2O2) was added at 100 ml/well for developing color
and read by an ELISA reader at 405 nm. Absorption values (O.D
values) were recorded and presented as the levels of antigen
specific antibodies for comparison.
Analysis of serum neutralizing activity
Serum neutralizing activity was analyzed by a pseudovirion
neutralization assay as described previously [34]. Pseudoviruses
were produced by co-transfection of 293T cells with a cDNA
construct for Env-deficient HIV NL-4 and a DNA construct
expressing the HIV SF162, HIV 89.6, HIV PVO.4 (SVPB11),
HIV AC10.029 (SVPB13), HIV PRHPA4259 (SVPB14), SIV-
4E10, or SIVmac239 EnvTr proteins. The env genes for HIV
SF162, HIV 89.6, HIV PVO.4 (SVPB11), HIV AC10.029
(SVPB13), and HIV PRHPA4259 (SVPB14) were obtained from
NIH ARRRP. Construction of the SIVmac239 EnvTr has been
described previously [38]. Construction of the SIV-4E10 env gene
was carried out essentially as described by Yuste et al. [37], in
which two amino acid residues in the SIVmac239 EnvTr, Leu-684
and Ala-685, were changed into the corresponding amino acid
residues in the HIV 89.6 Env (Ile and Thr respectively) by site-
directed mutagenesis. We also constructed SIV-2F5 and SIV-2F5/
4E10 env genes by mutating amino acids Lys-671, Asn-673, Ser-
674, Asp-676, and Val-677 in the backbone of SIVmac239 EnvTr
or SIV-4E10 respectively following the same approach. However,
SIV-2F5 and SIV-2F5/4E10 pseudovirions exhibited very low
infectivity similarly as reported by Yuste et al. [37] and they were
not used in neutralization assays. After preparation, pseudoviruses
were tittered in TMZ-bl cells and stored at 280uC until use.
For analysis of sera neutralizing activity, TMZ-bl cells were
seeded at 40,000 cells per well in a 96-well plate in 10% FCS-
DMEM media overnight at 37uC with 5% CO2. Serum samples
collected from guinea pigs that were heat-inactivated at 56uC for
30 min. Pseudoviruses (100 infectious particles) were incubated
with heat-inactivated sera at 1:50 dilution in 50 ml 10% FCS-
DMEM. Pseudovirions incubated with 10% FCS-DMEM only
were used as controls. The virus-serum mixtures were prepared in
triplicates and incubated at 37uC for 1 hr and then added to
TMZ-bl cells with an additional 150 ml of 10% FCS-DMEM plus
DEAE-Dextran (at a final concentration of 15 mg/ml). Two days
after infection, medium was removed and the cells were fixed and
stained as described in our previous studies [57]. Neutralization
was calculated as: (average number of blue foci in control wells –
average number of blue foci in sample wells)/(average number of
blue foci in control wells) X 100%, and presented as percentage of
neutralization. Peptide competition was carried out to confirm
MPER-specific neutralizing activity of sera from vaccinated guinea
pigs. Briefly, 1 ul guinea pig sera were incubated with 0.1 ug of the
2F5/4E10 peptide or a control peptide (AMQMLKETI, which
corresponds to a segment in the HIV Gag protein and was
synthesized at the Emory University Microchemical Facility,
purity.70%) in 40 ul 10% FCS-DMEM at 37uC for 1 hr,
followed by addition of 100 infectious units of pseudoviruses
diluted in 10 ul 10% FCS-DMEM (to a total volume of 50 ul and
a final serum dilution at 1:50) and further incubation at 37uC for
1 hr. After incubation, the peptide-serum-pseudovirus mixtures
(prepared in triplicates) were added to TMZ-bl cells with an
additional 150 ml of 10% FCS-DMEM plus DEAE-Dextran (at a
final concentration of 15 mg/ml) to determine virus neutralization
as described above.
Supporting Information
Figure S1 Amino acid sequence for HA-CI4S/gp41. The
Cys14-Ser mutation in the HA1 subunit indicated by (*) and
amino acid sequence from HIV 89.6 Env gp41 was underlined.
Found at: doi:10.1371/journal.pone.0014813.s001 (0.07 MB TIF)
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